Last reviewed · How we verify
Selg1 (CRIZANLIZUMAB)
Selg1 works by binding to P-selectin, preventing it from interacting with its ligands.
Selg1 (Crizanlizumab) is a selectin blocker developed by Novartis Pharmaceuticals Corp, targeting P-selectin to treat vaso-occlusive crisis in sickle cell disease. It was FDA-approved in 2019 and remains a patented product. As a small molecule, it works by binding to P-selectin, preventing it from interacting with its ligands and thereby reducing the frequency of vaso-occlusive crises. Key safety considerations include the potential for infusion reactions and thrombocytopenia. Selg1 is a valuable treatment option for patients with sickle cell disease.
At a glance
| Generic name | CRIZANLIZUMAB |
|---|---|
| Sponsor | Novartis |
| Drug class | Selectin Blocker [EPC] |
| Target | P-selectin |
| Modality | Monoclonal antibody |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2019 |
Mechanism of action
Crizanlizumab-tmca is humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions with its ligands, including P-selectin glycoprotein ligand (PSGL-1). Crizanlizumab-tmca can also dissociate preformed P-selectin/PSGL-1 complex. Binding P-selectin on the surface of the activated endothelium and platelets blocks interactions between endothelial cells, platelets, red blood cells, and leukocytes.
Approved indications
- Vaso-occlusive crisis in sickle cell disease
Common side effects
- Nausea
- Abdominal pain
- Arthralgia
- Back pain
- Pyrexia
- Oropharyngeal pain
- Diarrhea
- Vomiting
- Pruritus
- Musculoskeletal chest pain
- Myalgia
- Infusion-site reaction
Key clinical trials
- Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises (PHASE2)
- A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) (PHASE3)
- Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients (PHASE3)
- A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism (PHASE2)
- MAP to Provide Access to Crizanlizumab, for Sickle Cell Disease Patients
- Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study (PHASE4)
- Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients (PHASE2)
- An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Selg1 CI brief — competitive landscape report
- Selg1 updates RSS · CI watch RSS
- Novartis portfolio CI